Medpace Holdings, Inc.

DB:01P Stock Report

Market Cap: €13.6b

Medpace Holdings Valuation

Is 01P undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 01P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 01P (€477.7) is trading below our estimate of future cash flow value (€589.46)

Significantly Below Future Cash Flow Value: 01P is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 01P?

Key metric: As 01P is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 01P. This is calculated by dividing 01P's market cap by their current earnings.
What is 01P's PE Ratio?
PE Ratio33.7x
EarningsUS$460.40m
Market CapUS$15.52b

Price to Earnings Ratio vs Peers

How does 01P's PE Ratio compare to its peers?

The above table shows the PE ratio for 01P vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average52.7x
SRT3 Sartorius
97.4x21.01%€14.5b
1SXP SCHOTT Pharma KGaA
18.2x9.52%€2.6b
DIVISLAB Divi's Laboratories
69.1x17.01%₹1.7t
2269 WuXi Biologics (Cayman)
26x13.83%HK$142.3b
01P Medpace Holdings
33.7x9.40%€15.5b

Price-To-Earnings vs Peers: 01P is good value based on its Price-To-Earnings Ratio (33.7x) compared to the peer average (52.1x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 01P's PE Ratio compare vs other companies in the European Life Sciences Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
01P 33.7xIndustry Avg. 37.1xNo. of Companies4PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 01P is good value based on its Price-To-Earnings Ratio (33.7x) compared to the Global Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is 01P's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

01P PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.7x
Fair PE Ratio34.2x

Price-To-Earnings vs Fair Ratio: 01P is good value based on its Price-To-Earnings Ratio (33.7x) compared to the estimated Fair Price-To-Earnings Ratio (34.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 01P forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€477.70
€386.91
-19.01%
10.58%€431.84€287.02n/a12
Jun ’27€386.90
€377.78
-2.36%
10.49%€422.28€280.67n/a12
May ’27€355.60
€377.78
+6.24%
10.49%€422.28€280.67n/a12
Apr ’27€421.80
€436.37
+3.45%
14.30%€523.56€287.09n/a12
Mar ’27€380.60
€413.20
+8.56%
14.68%€493.89€279.19n/a12
Feb ’27€488.50
€470.27
-3.73%
17.74%€568.72€283.50n/a12
Jan ’27€480.70
€462.85
-3.71%
17.15%€559.44€281.00n/a12
Dec ’26€505.20
€467.42
-7.48%
17.45%€568.80€285.70n/a12
Nov ’26€506.00
€446.55
-11.75%
17.94%€563.17€282.87n/a11
Oct ’26€461.80
€362.98
-21.40%
14.91%€433.45€259.22n/a11
Sep ’26€403.80
€350.74
-13.14%
15.65%€436.00€260.74n/a11
Aug ’26€363.90
€354.31
-2.63%
15.65%€440.44€263.40n/a11
Jul ’26€271.30
€258.51
-4.72%
6.30%€294.43€232.44€477.7012
Jun ’26€259.20
€265.98
+2.61%
6.58%€302.91€239.14€386.9011
May ’26€271.00
€265.98
-1.85%
6.58%€302.91€239.14€355.6011
Apr ’26€275.10
€315.97
+14.86%
10.55%€373.42€273.59€421.8011
Mar ’26€313.40
€329.62
+5.18%
10.98%€386.18€282.95€380.6010
Feb ’26€334.70
€327.81
-2.06%
10.13%€381.36€282.21€488.5010
Jan ’26€322.30
€331.50
+2.85%
8.99%€381.12€282.03€480.7010
Dec ’25€321.40
€331.50
+3.14%
8.99%€381.12€282.03€505.2010
Nov ’25€294.50
€323.86
+9.97%
9.71%€374.55€274.42€506.0010
Oct ’25€299.60
€340.44
+13.63%
12.69%€389.59€265.10€461.8010
Sep ’25€320.20
€366.81
+14.56%
12.09%€403.11€274.30€403.8010
Aug ’25€355.00
€366.81
+3.33%
12.09%€403.11€274.30€363.9010
Jul ’25€379.10
€400.85
+5.74%
12.14%€448.46€276.55€271.309
€389.76
Fair Value
22.6% overvalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/02 11:47
End of Day Share Price 2026/07/01 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medpace Holdings, Inc. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric ColdwellBaird
Luke SergottBarclays
Sean DodgeBMO Capital Markets Equity Research